Treatment of patients with myelodysplastic syndromes: A review

Leukemic transformation (LT) free survival was studied in 30 patients with myelodysplastic syndromes (MDS). In 15 cases, 4-6 micrograms/day of 1-hydroxyvitamin D3 was administered, for a median duration of 17 months (D-group), other subjects had no therapy (N group). LT free survival of the D group had significant advantage over that of the N group according to the Kaplan-Meier method (P less than 0.001). In addition, 7 cases in the N group developed acute leukemia, in contrast to only one in the D group (P less than 0.05). These results suggest that oral administration of 1-hydroxyvitamin D3 prevents the progression of MDS to overt leukemia under the effect of differentiation capacity from blasts to monocytes.

show abstract

Bone marrow transplantation for acute monocytic leukemia following the treatment of hodgkin's disease

Russell¹,

Houwen²,

Ruether³

et al. 1986

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

A 32-year-old woman developed acute monocytic leukemia within a year of treatment for Hodgkin's disease with chemotherapy and radiation. Residual leukemia was present in the bone marrow after two induction courses of high-dose Ara-C. She received a bone marrow transplant from an HLA- and DR-identical sister and remains in complete remission more than 2 years after transplantation. Only one other instance of a remission greater than 2 years after transplantation for secondary acute leukemia could be found in the literature. Although bone marrow transplantation may be carried out successfully in these patients, it is possible that they may be more vulnerable to transplant-related complications because of their previous exposure to chemotherapy and radiation. Only further study can clarify this matter and determine the best time for the procedure and which regimen should be used.

show abstract

Treatment of patients with myelodysplastic syndromes: A review

Cited by 20 publications

References 37 publications

Hematologic benefits of 1-hydroxyvitamin D3 in an elderly patient with chronic myelodysplastic syndrome

Hematologic benefits of 1-hydroxyvitamin D3 in an elderly patient with chronic myelodysplastic syndrome

The effect of 1‐hydroxyvitamin D₃ for prolongation of leukemic transformation‐free survival in myelodysplastic syndromes

Bone marrow transplantation for acute monocytic leukemia following the treatment of hodgkin's disease

Contact Info

Product

Resources

About

Treatment of patients with myelodysplastic syndromes: A review

Cited by 20 publications

References 37 publications

Hematologic benefits of 1-hydroxyvitamin D3 in an elderly patient with chronic myelodysplastic syndrome

Hematologic benefits of 1-hydroxyvitamin D3 in an elderly patient with chronic myelodysplastic syndrome

The effect of 1‐hydroxyvitamin D3 for prolongation of leukemic transformation‐free survival in myelodysplastic syndromes

Bone marrow transplantation for acute monocytic leukemia following the treatment of hodgkin's disease

Contact Info

Product

Resources

About

The effect of 1‐hydroxyvitamin D₃ for prolongation of leukemic transformation‐free survival in myelodysplastic syndromes